6547 高端疫苗歷年利潤比率
| 年度/季別 | 毛利率 | 營業利益率 | 稅前淨利率 | 稅後淨利率 |
|---|
| 2025Q2 | 69.74% | -42.95% | -68.95% | -68.95% |
| 2025Q1 | 65.04% | -28.48% | -18.23% | -18.23% |
| 2024Q4 | 55.75% | -34.90% | -17.17% | -17.17% |
| 2024Q3 | 57.31% | 3.56% | 0.62% | 0.62% |
| 2024Q2 | 80.14% | -1.52% | 7.74% | 7.74% |
| 2024Q1 | 76.66% | -182.08% | -125.28% | -125.28% |
| 2023Q4 | 69.39% | -318.57% | -339.76% | -339.76% |
| 2023Q3 | 51.00% | -39.85% | -23.84% | -23.84% |
| 2023Q2 | - | - | - | - |
| 2023Q1 | - | - | - | - |
| 2022Q4 | -1769.47% | -2929.21% | -3021.99% | -3021.99% |
| 2022Q3 | 98.04% | -17752.05% | -14768.77% | -14768.77% |
| 2022Q2 | -38.21% | -2526.45% | -2446.14% | -2446.14% |
| 2022Q1 | 64.31% | -46.38% | -42.97% | -42.97% |
| 2021Q4 | 70.46% | 51.66% | 52.50% | 52.50% |
| 2021Q3 | 70.08% | 52.39% | 54.55% | 54.55% |
| 2021Q2 | 19.29% | -48771.17% | -19160.45% | -19160.45% |
| 2021Q1 | 21.67% | -9009.35% | -4992.08% | -4992.08% |
| 2020Q4 | 67.06% | -3747.18% | -2699.41% | -2699.41% |
| 2020Q3 | 55.24% | -6933.16% | -6206.27% | -6206.27% |
| 2020Q2 | 76.63% | -14996.26% | -15011.55% | -15011.55% |